MEDI 0639

Drug Profile

MEDI 0639

Alternative Names: Anti-DLL-4 MAb; MEDI0639

Latest Information Update: 28 May 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator MedImmune
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action DLL4 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Small cell lung cancer
  • Discontinued Solid tumours

Most Recent Events

  • 28 May 2018 No recent reports of development identified for phase-I development in Small-cell-lung-cancer in USA (IV)
  • 12 Sep 2016 Discontinued - Phase-I for Solid tumours (Late-stage disease) in USA (IV)
  • 08 Oct 2015 Phase-I development for Solid tumours (Late-stage disease) is ongoing in USA (NCT01577745)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top